April 23rd 2025
The investment will be done over five years and will include new, state-of-the-art R&D facilities as well as new or expanded manufacturing sites in multiple US states.
NGS abbreviates drug discovery timelines.
Sartorius Stedim's New Testing Services to Focus on mAbs and biosimilars
May 5th 2017Operated by BioOutsource, Sartorius’ subsidiary, the Glasgow, UK-based service center will offer physicochemical properties and structural attributes testing and allow clients to perform structural and functional analyses in parallel.